Casdin Capital, LLC - Q1 2019 holdings

$910 Million is the total value of Casdin Capital, LLC's 29 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was - .

 Value Shares↓ Weighting
ALEC NewALECTOR INC$6,197,000331,039
+100.0%
0.68%
GILD NewGILEAD SCIENCES INC$5,201,00080,000
+100.0%
0.57%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
BLUEPRINT MEDICINES CORP32Q3 20239.6%
ALNYLAM PHARMACEUTICALS INC32Q3 20239.9%
AGIOS PHARMACEUTICALS INC27Q2 202212.1%
GLOBAL BLOOD THERAPEUTICS IN27Q2 20227.1%
FATE THERAPEUTICS INC26Q3 20238.3%
BIOLIFE SOLUTIONS INC22Q3 202314.9%
CODEXIS INC22Q3 20238.1%
SAREPTA THERAPEUTICS INC21Q3 202313.6%
BLUEBIRD BIO INC21Q4 20207.8%
ILLUMINA INC21Q3 20236.0%

View Casdin Capital, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Casdin Capital, LLC Q1 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Absci CorpMay 08, 20234,448,2604.8%
CODEXIS, INC.Sold outFebruary 14, 202300.0%
DermTech, Inc.Sold outFebruary 14, 202300.0%
Invitae CorpFebruary 14, 20239,038,3883.7%
Magenta Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Tango Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Verve Therapeutics, Inc.February 14, 20232,290,5713.7%
Tenaya Therapeutics, Inc.December 07, 20226,427,2009.9%
Fulcrum Therapeutics, Inc.February 11, 20211,241,1764.5%
Gritstone Oncology, Inc.Sold outFebruary 11, 202100.0%

View Casdin Capital, LLC's complete significant-ownership history.

Latest filings
TypeFiled
42024-06-21
42024-06-12
42024-06-05
SC 13D/A2024-06-03
42024-05-31
42024-05-28
42024-05-28
42024-05-22
SC 13D/A2024-05-22
42024-05-17

View Casdin Capital, LLC's complete filings history.

Compare quarters

Export Casdin Capital, LLC's holdings